ATRC, US04963C2098

AtriCure stock fell 4.8 percent as analysts reset targets

Published on 10/07/2026 at 03:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AtriCure's second-quarter revenue reached USD 153.6 million on July 23, 2026, beating the USD 151.8 million forecast. Fiscal 2026 EPS guidance is USD 0.24-0.32.

ATRC, US04963C2098, Illustration mit AI erstellt.

AtriCure stock (ISIN US04963C2098) closed at USD 53.68 on October 6, 2026, after falling 4.8 percent. The move leaves the medical device company between its 52-week low of USD 25.36 and high of USD 61.70, while its latest quarterly figures provide a stronger operating reference.

Revenue beats the quarterly forecast

According to MarketBeat in its October 1, 2026 report, AtriCure generated USD 153.6 million of revenue in the second quarter of 2026, compared with a USD 151.8 million analyst estimate. The result was 1.2 percent above that forecast.

The same report put quarterly earnings per share at USD 0.18, versus an expected loss of USD 0.01. AtriCure's standardized financial data also show USD 8.96 million of consolidated net income and a 6.0 percent operating margin for the quarter ended June 30, 2026.

Analysts weigh growth against valuation

MarketBeat described the analyst consensus as Moderate Buy, based on 12 ratings: one Strong Buy, seven Buys and four Holds. The average price target was USD 53.30, leaving the October 6 closing price 0.7 percent above that target.

As Investing.com reported on October 2, 2026, Freedom Capital downgraded AtriCure from Buy to Hold while raising its price target from USD 43 to USD 57. The firm cited expected BoX-NoAF study data, but also pointed to caveats in earlier supportive evidence.

That combination matters for the stock. The second-quarter beat supports the current earnings case, while the target spread shows that analysts are already weighing future procedure growth against execution and clinical-data risk.

AtriCure operates in cardiac care

AtriCure develops technologies for atrial fibrillation treatment, left atrial appendage management and postoperative pain management. Its portfolio includes the Isolator Synergy Ablation System, AtriClip products and cryoablation systems.

Stock stays below yearly high

AtriCure's October 6 closing price of USD 53.68 on Nasdaq was 13.0 percent below the 52-week high of USD 61.70. The company had a market capitalization of USD 2.7 billion as of October 6, 2026, placing the earnings beat alongside a valuation that leaves limited room for execution setbacks.